Chronic kidney disease trials recruiting in Arizona

All Chronic kidney disease trials nationally

Cities in Arizona

Recruiting trials in Arizona

• A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure
  NCT06742723 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Surprise, Tucson
• A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
  NCT07662135 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Sun City, Surprise
• A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.
  NCT07222917 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Surprise
• A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
  NCT04671771 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 90 Years · Sex: All (male and female) · Arizona: Phoenix
• A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
  NCT07753993 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Peoria, Phoenix, Surprise
• A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
  NCT05457283 · Phase: Phase 3 · Ages: 1 Year to 18 Years · Sex: All (male and female) · Arizona: Phoenix
• American Indian Chronic Renal Insufficiency Cohort Study (AI-CRIC Study)
  NCT04185844 · Phase: Not specified · Ages: 21 Years to 80 Years · Sex: All (male and female) · Arizona: Phoenix
• Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment
  NCT07403669 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Chandler, Gilbert, Phoenix, San Tan Valley
• Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
  NCT05334069 · Phase: Not specified · Ages: 40 Years to 75 Years · Sex: All (male and female) · Arizona: Kingman, Phoenix
• Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
  NCT05485961 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Glendale, Phoenix, Tucson
• EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
  NCT06531824 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Surprise
• Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
  NCT06712407 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Glendale
• Kidney Precision Medicine Project
  NCT04334707 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Tucson
• Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
  NCT06190717 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 84 Years · Sex: All (male and female) · Arizona: Phoenix, Tucson
• Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus
  NCT07187479 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Phoenix, Scottsdale
• REgulatory T Cell Therapy to Achieve Immunosuppression REduction
  NCT06552169 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Arizona: Phoenix
• SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
  NCT06001827 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Arizona: Bullhead City, Marana, Phoenix, Tucson